Hanmi Pharmaceutical Shares Plunge 7.73% Despite Approval of Domestic Obesity Drug 'Effe' — Trading at 418,000 Won as Market Reaction Splits Amid Competition with Wegovy and Mounjaro
Hanmi Pharmaceutical's stock is falling sharply despite winning product approval for its domestically developed GLP-1-based obesity treatment 'Effe (ingredient name: epeleglenatide).' The case is drawing attention as an example showing that expectations for growth in the obesity treatment market do

Hanmi Pharmaceutical's stock is falling sharply despite winning product approval for its domestically developed GLP-1-based obesity treatment 'Effe (ingredient name: epeleglenatide).' The case is drawing attention as an example showing that expectations for growth in the obesity treatment market do not necessarily align with an individual company's stock price movement.
▶ 7.73% Plunge Despite Approval 'Good News'
On the morning of the 14th, Hanmi Pharmaceutical was trading at 418,000 won, down 35,000 won from the previous day, a decline of 7.73%. In the previous day's supply and demand, individuals and institutions showed selling pressure, while foreigners and program trading showed buying.
Hanmi Pharmaceutical announced on the 7th that it had obtained domestic product approval from the Ministry of Food and Drug Safety for the GLP-1-based new obesity drug 'Effe.' The approval is significant in that a domestically developed new drug has emerged as a new competitor in the domestic obesity treatment market, which has been dominated by imported medicines.
▶ Wegovy and Mounjaro Lead the Field as Domestic New Drug Joins
Until now, Novo Nordisk's Wegovy and Eli Lilly's Mounjaro have been the key competing products in the domestic GLP-1-based obesity treatment market. With Hanmi Pharmaceutical's Effe joining them, changes are expected in the competitive landscape of the domestic market.
Hanmi Pharmaceutical emphasizes that Effe was developed based on its proprietary technology and that clinical evidence has been secured in Korean subjects. Clinical data reflecting the characteristics of domestic patients could serve as a reference factor in choosing the treatment in medical settings.
▶ Approval ≠ Performance… Variables That Will Determine Competitiveness
However, product approval does not immediately translate into expanded market share or improved earnings. In the actual market, factors such as drug pricing, patient burden, prescribing convenience, supply stability, and clinical differentiation from existing treatments act as variables determining competitiveness.
In particular, the obesity treatment market is seeing its competitive arena expand beyond simple weight-loss effects to long-term safety, treatment persistence rates, and improvements in metabolic diseases.
Hanmi Pharmaceutical is also developing next-generation obesity treatment candidates beyond Effe. Its development pipeline includes HM15275, a triple agonist targeting GLP-1, GIP, and glucagon receptors.
▶ Different Business Structures by Company… Investor Assessments May Diverge
Domestic companies in the obesity treatment space also differ in their business structures. While Hanmi Pharmaceutical is focused on developing, approving, and commercializing its own new drugs, Peptron is exploring commercialization opportunities with global pharmaceutical companies based on its long-acting drug delivery technology. Even if expectations for obesity treatment market growth are high, investor assessments may vary depending on each company's technology development stage and revenue-generation structure.
Hanmi Pharmaceutical's stock decline on the day needs to be examined from this perspective. Although the business achievement of Effe's approval has been confirmed, further confirmation is needed on how much that achievement will contribute to future sales and operating profit. The fact that selling by individuals and institutions and buying by foreigners and program trading clashed the previous day is also noteworthy, but it is difficult to attribute the day's plunge solely to that supply and demand.
▶ Key Points Ahead: Prescription Expansion and Market Settling After Launch
Going forward, market attention is expected to focus on whether prescriptions expand and how quickly the drug settles into the market after Effe's actual launch. How much ground a domestic new drug can secure in a market where Wegovy and Mounjaro compete is a key factor to watch.
Hanmi Pharmaceutical's stock, which fell to 418,000 won on the 14th, shows that the growth potential of the obesity treatment market and short-term investment sentiment on individual stocks can move in different directions. The emergence of a domestic new obesity drug has ushered the domestic market into a new phase of competition, but for that achievement to translate into a stock price recovery, actual sales performance and business profitability need to be confirmed.
[This article was written based on intraday market prices provided and company announcements. Stock prices may fluctuate during trading hours, and post-approval sales performance and market outlooks may differ from actual results. This is not a recommendation to invest in any particular stock, and investment decisions and responsibility rest with the investor. AI assistance was used in writing this article.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] US October Retail Sales Rise 6.8% Year-on-Year, 0.2% Month-on-Month... Economic Indicators in Focus After CPI and PPI](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627311%2Fa2376e0512277714%2Fvariants%2Fhero.webp&w=1920&q=75)
![[Breaking] Cyberattack via Optimizely Exposes 178 Global Organizations... CNN, BBC, HSBC, and Ledger Also Affected](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F627874%2Ffc472b72a2596aa1%2Fvariants%2Fhero.webp&w=1920&q=75)

